HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Taxol neuropathy. Electrodiagnostic and sural nerve biopsy findings.

Abstract
Taxol has recently been approved for the treatment of ovarian cancer that has failed to respond to other chemotherapeutic agents. A predominantly sensory neuropathy has been reported in patients receiving taxol, but corresponding nerve changes have not been described. The patient described herein received taxol at a dose of 275 mg/m2 every 21 days. The sural nerve biopsy performed after 17 courses of taxol (cumulative dose, 6603 mg) showed severe nerve fiber loss, axonal atrophy, and secondary demyelination. Axonal regeneration was absent. The findings are compatible with a cell body disease or a length-dependent, distal neuropathy with failure of axonal regeneration. The findings observed in taxol-induced neuropathy are important to document for comparison with other neoplastic and paraneoplastic neuropathies affecting patients with cancer.
AuthorsZ Sahenk, R Barohn, P New, J R Mendell
JournalArchives of neurology (Arch Neurol) Vol. 51 Issue 7 Pg. 726-9 (Jul 1994) ISSN: 0003-9942 [Print] United States
PMID7912506 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Paclitaxel
Topics
  • Electrodiagnosis
  • Female
  • Humans
  • Middle Aged
  • Paclitaxel (adverse effects)
  • Peripheral Nervous System Diseases (chemically induced, pathology)
  • Sural Nerve (pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: